This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Zoetis (ZTS) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Zoetis (ZTS) Gained But Lagged the Market Today
by Zacks Equity Research
Zoetis (ZTS) closed the most recent trading day at $164.84, moving +0.81% from the previous trading session.
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
4 Stocks in Focus That Declared Dividend Hikes Amid Market Volatility
by Ritujay Ghosh
Stocks like PCAR, ZTS, AVGO and TGLS recently announced dividend hikes.
Here's Why Zoetis (ZTS) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?
by Zacks Equity Research
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SDZNY vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
by Zacks Equity Research
ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
Compared to Estimates, Zoetis (ZTS) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 8.22% and 4.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis
by Zacks Equity Research
Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.
Gear Up for Zoetis (ZTS) Q3 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis Gears Up to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in third-quarter 2024 in both the United States and International segments.
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Zoetis (ZTS) closed at $182.76 in the latest trading session, marking a +1.53% move from the prior day.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Ensign Group (ENSG) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.46% and 1.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?